OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
March 12, 2020
The project, which will be titled the COVID-19 Therapeutics Accelerator, will work to pinpoint which new and repurposed drugs and biologics can treat patients immediately, and which can treat patients long-term.
March 11, 2020
Through the agreement, Emergent will manufacture the vaccine, which is formulated based on Novavax’s proprietary recombinant protein nanoparticle technology platform and its Matrix-M adjuvant to boost immune responses.
March 10, 2020
New dates for the postponed event are still being determined.
March 09, 2020
The company is using its LEAPS peptide technology to develop the immunotherapy, which may be able to reduce COVID-19 viral load and tissue damage.
March 06, 2020
The Indian government has issued a notification of the restriction on the export of 26 APIs and formulations, including paracetamol, progesterone, and vitamin B12, as a result of the outbreak of COVID-19.
The conference, which was originally scheduled for March 31–April 3, 2020 at the Messe München in Germany, will be rescheduled for Oct. 19–22, 2020 at the same location.
The action involves allowing specific National Institute for Occupational Safety and Health-approved respirators not regulated by FDA to be used in healthcare settings to increase the number of respirators available in the United States.
The acquisition will expand Nexelis’ immunology testing expertise.
March 05, 2020
The organization is postponing its annual meeting to July 2020 because of the developing COVID-19 outbreak.
The therapy works by transferring pathogen-specific antibodies from plasma gathered from recovered individuals into an infected patient, which may help the patient’s immune system respond and increase recovery.